Development of Quinoline-Based Theranostic Ligands for the Targeting of Fibroblast Activation Protein

10.1101/gad.279737.116

10.1074/jbc.274.51.36505

Rettig, 1993, Regulation and heteromeric structure of the fibroblast activation protein in normal and transformed cells of mesenchymal and neuroectodermal origin, Cancer Res., 53, 3327

10.1073/pnas.87.18.7235

10.1158/1078-0432.CCR-06-1746

10.1097/MPA.0b013e31816618ce

10.1016/j.canlet.2011.01.011

10.1309/AJCP86PPBNGOHNNL

10.1023/A:1023055600919

10.1111/j.1742-4658.2011.08051.x

10.1158/0008-5472.CAN-03-3184

10.1016/j.drup.2005.03.002

10.1074/jbc.274.35.24947

10.1172/JCI26532

10.1126/science.1195300

Welt, 1994, Antibody targeting in metastatic colon cancer: a phase I study of monoclonal antibody F19 against a cell-surface protein of reactive tumor stromal fibroblasts, J Clin Oncol., 12, 1193, 10.1200/JCO.1994.12.6.1193

Scott, 2003, A phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer, Clin Cancer Res., 9, 1639

10.1159/000069863

10.1158/2326-6066.CIR-13-0027

10.1158/0008-5472.CAN-14-3041

10.1158/1078-0432.CCR-07-5211

10.1093/jnci/djs336

10.1158/1535-7163.MCT-08-1170

10.1158/0008-5472.CAN-05-2805

Teichgräber, 2015, Specific inhibition of fibroblast activation protein (FAP)-alpha prevents tumor progression in vitro, Adv Med Sci., 60, 264, 10.1016/j.advms.2015.04.006

Loktev A Lindner T Mier W . A new method for tumor imaging by targeting cancer associated fibroblasts. J Nucl Med. April 6, 2018 [Epub ahead of print].

10.1158/1078-0432.CCR-12-0644

10.1021/jm500031w

10.1021/tx200211v

Testa, 2000, The influence of lipophilicity on the pharmacokinetic behavior of drugs: concepts and examples, Perspect Drug Discov Des., 19, 179, 10.1023/A:1008741731244